|
業務類別
|
Biotechnology |
|
業務概覽
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
| 公司地址
| 3020 Callan Road, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 401-7900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.aviditybiosciences.com |
| 員工數量
| 511 |
| Mr. John B. Moriarty, J.D.,Jr |
Chief Legal Officer and Corporate Secretary |
美元 208.33K |
29/04/2025 |
| Ms. Kathleen P. Gallagher |
Chief Program Officer |
-- |
29/04/2025 |
| Ms. Teresa McCarthy |
Chief Human Resources Officer |
美元 456.90K |
29/04/2025 |
| Ms. Sarah Boyce |
Director, President and Chief Executive Officer |
美元 659.90K |
29/04/2025 |
| Mr. Joseph T. Baroldi |
Chief Operating Officer |
美元 439.90K |
06/01/2022 |
| Mr. Eric Mosbrooker |
Chief Commercial Officer |
-- |
29/04/2025 |
| Dr. W. Michael Flanagan, PhD |
Chief Scientific |
美元 500.30K |
29/04/2025 |
| Dr. Arthur A. Levin,PhD |
Distinguished Scientist and Strategic Leader and Director |
-- |
29/04/2025 |
| Mr. Michael F. Maclean |
Chief Business Officer, Chief Financial Officer and Principal Accounting Officer |
美元 490.80K |
10/06/2025 |
| Mr. Steven George Hughes, M.D. |
Chief Medical Officer |
-- |
29/04/2025 |
| Mr. Charles Calderaro, III |
Chief Technical Officer |
-- |
29/04/2025 |
|
|
| Dr. Noreen Roth Henig, M.D. |
Independent Director |
29/04/2025 |
| Ms. Tamar Thompson |
Independent Director |
29/04/2025 |
| Ms. Jean Kim |
Independent Director |
29/04/2025 |
| Ms. Simona Skerjanec, M.B.A. |
Independent Director |
29/04/2025 |
| Ms. Sarah Boyce |
Director, President and Chief Executive Officer |
29/04/2025 |
| Dr. Arthur A. Levin,PhD |
Distinguished Scientist and Strategic Leader and Director |
29/04/2025 |
| Mr. Carsten Boess |
Independent Director |
29/04/2025 |
| Dr. Edward M. Kaye, M.D. |
Independent Director |
29/04/2025 |
| Dr. Troy E. Wilson, PhD, J.D. |
Chairman of the Board |
29/04/2025 |
|
|
|
|
